Abstract：
UNASSIGNED: The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan.
UNASSIGNED: This retrospective, chart review-based, non-interventional study collected data on RRMM patients (≥20 years old) receiving pomalidomide-based treatment between January 2017 and December 2020 across five sites in Taiwan.
UNASSIGNED: Median age of the study population was 65.6 years. Approximately 75% patients received a doublet regimen and 25% were on a triplet regimen. Disease progression was the most common cause for switching to pomalidomide-based treatments in doublet (71.2%) and triplet (58.3%) groups. Patients in doublet and triplet groups (>80%) received 4 mg pomalidomide as a starting dose. Overall response rate (ORR: 31.5% and 45.8%) and median progression-free survival (PFS: 4.7 and 6.8 months) were reported in the doublet and triplet regimen. Doublet regimen was discontinued mainly due to disease progression or death (78.1%); however, triplet regimen patients mainly terminated their treatment due to reimbursement limitations (29.2%). Healthcare resource utilization (HRU) was comparable between doublet and triplet groups.
UNASSIGNED: In Taiwan, half of RRMM patients received pomalidomide-based triplet regimens. Triplet regimens showed a trend towards better outcomes with longer PFS and higher response rates compared to doublets. Notably, the duration of triplet use is influenced by reimbursement limitations. This study provides insight into RRMM treatment patterns in Taiwan and the findings suggest that triplet regimens may be a better alternative than doublet regimens.
UNASSIGNED: This retrospective, chart review-based, non-interventional study collected data on RRMM patients (≥20 years old) receiving pomalidomide-based treatment between January 2017 and December 2020 across five sites in Taiwan.
UNASSIGNED: Median age of the study population was 65.6 years. Approximately 75% patients received a doublet regimen and 25% were on a triplet regimen. Disease progression was the most common cause for switching to pomalidomide-based treatments in doublet (71.2%) and triplet (58.3%) groups. Patients in doublet and triplet groups (>80%) received 4 mg pomalidomide as a starting dose. Overall response rate (ORR: 31.5% and 45.8%) and median progression-free survival (PFS: 4.7 and 6.8 months) were reported in the doublet and triplet regimen. Doublet regimen was discontinued mainly due to disease progression or death (78.1%); however, triplet regimen patients mainly terminated their treatment due to reimbursement limitations (29.2%). Healthcare resource utilization (HRU) was comparable between doublet and triplet groups.
UNASSIGNED: In Taiwan, half of RRMM patients received pomalidomide-based triplet regimens. Triplet regimens showed a trend towards better outcomes with longer PFS and higher response rates compared to doublets. Notably, the duration of triplet use is influenced by reimbursement limitations. This study provides insight into RRMM treatment patterns in Taiwan and the findings suggest that triplet regimens may be a better alternative than doublet regimens.
摘要：
■在台湾，复发性/难治性多发性骨髓瘤（RRMM）的治疗前景正在迅速发展。本研究旨在评估台湾RRMM患者的治疗模式。
■这次回顾展，基于图表审查，非介入性研究收集了2017年1月至2020年12月间在台湾5个地点接受基于泊马度胺的治疗的RRMM患者(≥20岁)的数据.
■研究人群的中位年龄为65.6岁。大约75％的患者接受了双联方案，25％的患者接受了三联方案。在双联组（71.2％）和三联组（58.3％）中，疾病进展是转换为基于泊马度胺的治疗的最常见原因。双组和三联组（>80％）的患者接受4mg泊马度胺作为起始剂量。在双联和三联方案中报告了总体缓解率（ORR：31.5％和45.8％）和中位无进展生存期（PFS：4.7和6.8个月）。Doublet治疗方案终止主要是由于疾病进展或死亡（78.1%）；然而，三联方案患者主要因报销限制而终止治疗(29.2%).医疗资源利用率（HRU）在双组和三联组之间具有可比性。
■在台湾，一半的RRMM患者接受了基于泊马利度胺的三联疗法.与双联方案相比，三联方案显示出具有更长的PFS和更高的应答率的更好结果的趋势。值得注意的是,三联使用的持续时间受报销限制的影响。这项研究提供了对台湾RRMM治疗模式的见解，研究结果表明，三联疗法可能比双联疗法更好。
■这次回顾展，基于图表审查，非介入性研究收集了2017年1月至2020年12月间在台湾5个地点接受基于泊马度胺的治疗的RRMM患者(≥20岁)的数据.
■研究人群的中位年龄为65.6岁。大约75％的患者接受了双联方案，25％的患者接受了三联方案。在双联组（71.2％）和三联组（58.3％）中，疾病进展是转换为基于泊马度胺的治疗的最常见原因。双组和三联组（>80％）的患者接受4mg泊马度胺作为起始剂量。在双联和三联方案中报告了总体缓解率（ORR：31.5％和45.8％）和中位无进展生存期（PFS：4.7和6.8个月）。Doublet治疗方案终止主要是由于疾病进展或死亡（78.1%）；然而，三联方案患者主要因报销限制而终止治疗(29.2%).医疗资源利用率（HRU）在双组和三联组之间具有可比性。
■在台湾，一半的RRMM患者接受了基于泊马利度胺的三联疗法.与双联方案相比，三联方案显示出具有更长的PFS和更高的应答率的更好结果的趋势。值得注意的是,三联使用的持续时间受报销限制的影响。这项研究提供了对台湾RRMM治疗模式的见解，研究结果表明，三联疗法可能比双联疗法更好。
